Edwards Lifesciences Co. (NYSE:EW) Shares Acquired by FAS Wealth Partners Inc.

FAS Wealth Partners Inc. boosted its holdings in Edwards Lifesciences Co. (NYSE:EWFree Report) by 14.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 24,244 shares of the medical research company’s stock after buying an additional 2,993 shares during the period. FAS Wealth Partners Inc.’s holdings in Edwards Lifesciences were worth $1,849,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Castleview Partners LLC acquired a new stake in Edwards Lifesciences in the 1st quarter worth about $25,000. Compass Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 4th quarter worth about $31,000. Jackson Grant Investment Advisers Inc. purchased a new position in shares of Edwards Lifesciences in the 3rd quarter worth about $38,000. Janiczek Wealth Management LLC raised its holdings in shares of Edwards Lifesciences by 108.6% in the 3rd quarter. Janiczek Wealth Management LLC now owns 582 shares of the medical research company’s stock worth $40,000 after purchasing an additional 303 shares during the period. Finally, Sunbelt Securities Inc. purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth about $49,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at approximately $1,506,925.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $91.68, for a total value of $1,320,192.00. Following the completion of the sale, the vice president now owns 173,584 shares of the company’s stock, valued at approximately $15,914,181.12. The disclosure for this sale can be found here. Insiders sold a total of 189,604 shares of company stock worth $16,022,982 in the last three months. 1.29% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Wells Fargo & Company upgraded Edwards Lifesciences from an “equal weight” rating to an “overweight” rating and set a $94.00 target price on the stock in a report on Friday, February 2nd. Oppenheimer raised their target price on Edwards Lifesciences from $93.00 to $100.00 and gave the company an “outperform” rating in a report on Monday, March 18th. OTR Global upgraded Edwards Lifesciences from a “mixed” rating to a “positive” rating in a report on Tuesday, March 26th. Mizuho raised their target price on Edwards Lifesciences from $85.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Royal Bank of Canada raised their target price on Edwards Lifesciences from $82.00 to $95.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.80.

View Our Latest Stock Report on EW

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $94.30 on Wednesday. Edwards Lifesciences Co. has a twelve month low of $60.57 and a twelve month high of $96.12. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $56.76 billion, a price-to-earnings ratio of 41.00, a price-to-earnings-growth ratio of 4.67 and a beta of 1.05. The business has a 50 day simple moving average of $87.13 and a 200-day simple moving average of $76.46.

Edwards Lifesciences (NYSE:EWGet Free Report) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $0.64 EPS for the quarter, hitting analysts’ consensus estimates of $0.64. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.64 EPS. As a group, equities research analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Featured Articles

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EWFree Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.